210 related articles for article (PubMed ID: 22076965)
21. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
[TBL] [Abstract][Full Text] [Related]
22. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
Vlachos P; Joseph B
Oncogene; 2009 Nov; 28(47):4175-88. PubMed ID: 19734939
[TBL] [Abstract][Full Text] [Related]
23. Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells.
Bilodeau S; Roussel-Gervais A; Drouin J
Mol Cell Biol; 2009 Apr; 29(7):1895-908. PubMed ID: 19139274
[TBL] [Abstract][Full Text] [Related]
24. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.
Vlachos P; Nyman U; Hajji N; Joseph B
Cell Death Differ; 2007 Aug; 14(8):1497-507. PubMed ID: 17464323
[TBL] [Abstract][Full Text] [Related]
25. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes.
Gosselet FP; Magnaldo T; Culerrier RM; Sarasin A; Ehrhart JC
Cell Signal; 2007 Apr; 19(4):731-9. PubMed ID: 17112701
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of cell cycle arrest and terminal differentiation in a maximally proliferative human epithelial tissue: Lessons from the human hair follicle matrix.
Purba TS; Brunken L; Peake M; Shahmalak A; Chaves A; Poblet E; Ceballos L; Gandarillas A; Paus R
Eur J Cell Biol; 2017 Sep; 96(6):632-641. PubMed ID: 28413121
[TBL] [Abstract][Full Text] [Related]
27. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101.
Sinuani I; Weissgarten J; Beberashvili I; Rapoport MJ; Sandbank J; Feldman L; Albeck M; Averbukh Z; Sredni B
Nephrol Dial Transplant; 2009 Aug; 24(8):2328-38. PubMed ID: 19321762
[TBL] [Abstract][Full Text] [Related]
28. Genetic and Epigenetic Control of CDKN1C Expression: Importance in Cell Commitment and Differentiation, Tissue Homeostasis and Human Diseases.
Stampone E; Caldarelli I; Zullo A; Bencivenga D; Mancini FP; Della Ragione F; Borriello A
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614816
[TBL] [Abstract][Full Text] [Related]
29. Regulation of p57(KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation.
Figliola R; Busanello A; Vaccarello G; Maione R
J Mol Biol; 2008 Jul; 380(2):265-77. PubMed ID: 18513743
[TBL] [Abstract][Full Text] [Related]
30. The cyclin-dependent kinase inhibitor p27 kip1 regulates radial stem cell quiescence and neurogenesis in the adult hippocampus.
Andreu Z; Khan MA; González-Gómez P; Negueruela S; Hortigüela R; San Emeterio J; Ferrón SR; Martínez G; Vidal A; Fariñas I; Lie DC; Mira H
Stem Cells; 2015 Jan; 33(1):219-29. PubMed ID: 25185890
[TBL] [Abstract][Full Text] [Related]
31. The E2A splice variant E47 regulates the differentiation of projection neurons via p57(KIP2) during cortical development.
Pfurr S; Chu YH; Bohrer C; Greulich F; Beattie R; Mammadzada K; Hils M; Arnold SJ; Taylor V; Schachtrup K; Uhlenhaut NH; Schachtrup C
Development; 2017 Nov; 144(21):3917-3931. PubMed ID: 28939666
[TBL] [Abstract][Full Text] [Related]
32. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes.
Li G; Domenico J; Lucas JJ; Gelfand EW
J Immunol; 2004 Aug; 173(4):2383-91. PubMed ID: 15294951
[TBL] [Abstract][Full Text] [Related]
33. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer.
Liang B; Wang S; Yang X; Ye Y; Yu Y; Cui Z
Chin Med J (Engl); 2003 Jan; 116(1):20-3. PubMed ID: 12667381
[TBL] [Abstract][Full Text] [Related]
34. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70.
Zou P; Yoshihara H; Hosokawa K; Tai I; Shinmyozu K; Tsukahara F; Maru Y; Nakayama K; Nakayama KI; Suda T
Cell Stem Cell; 2011 Sep; 9(3):247-61. PubMed ID: 21885020
[TBL] [Abstract][Full Text] [Related]
35. CDK inhibitors selectively diminish cell cycle controlled activation of the histone H4 gene promoter by p220NPAT and HiNF-P.
Mitra P; Ghule PN; van der Deen M; Medina R; Xie RL; Holmes WF; Ye X; Nakayama KI; Harper JW; Stein JL; Stein GS; van Wijnen AJ
J Cell Physiol; 2009 May; 219(2):438-48. PubMed ID: 19170105
[TBL] [Abstract][Full Text] [Related]
36. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
37. Cellular Response upon Stress: p57 Contribution to the Final Outcome.
Rossi MN; Antonangeli F
Mediators Inflamm; 2015; 2015():259325. PubMed ID: 26491224
[TBL] [Abstract][Full Text] [Related]
38. Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study.
Bozdoğan O; Atasoy P; Batislam E; Başar MM; Başar H
Tumori; 2008; 94(4):556-62. PubMed ID: 18822693
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between expression of p57(kip2), cyclin E protein, PCNA, and clinicopathological factors in human pancreatic cancer].
Yue H; Zhang N; Feng XL; Ma SR; Song FL; Yang M; Tang YH
Ai Zheng; 2003 Jul; 22(7):705-9. PubMed ID: 12866960
[TBL] [Abstract][Full Text] [Related]
40. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors.
Starostina NG; Kipreos ET
Trends Cell Biol; 2012 Jan; 22(1):33-41. PubMed ID: 22154077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
